QC
VYGR icon

Quadrature Capital’s Voyager Therapeutics VYGR Stock Holding History

Quadrature Capital’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72.5K Buy
+20,702
New +$78.5K ﹤0.01% 1495
2026
Q1 		– Sell
-30,425
Closed -$120K – 1910
2025
Q4 		$120K Buy
+30,425
New +$135K ﹤0.01% 1070

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Quadrature Capital's VYGR Position: Q2 2026 in Review

Quadrature Capital opened a new position in Voyager Therapeutics (VYGR) in Q2 2026: 20,702 shares worth $72.5K. The stake represents ﹤0.01% of the portfolio and ranks #1495 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in VYGR as recently as Q4 2025.

Quadrature Capital first reported a position in VYGR in Q4 2025 and has held it in 2 quarters since. The position peaked at $120K in Q4 2025. 135 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Quadrature Capital held 20,702 shares of Voyager Therapeutics worth $72.5K as of Q2 2026.
  • Voyager Therapeutics was a new Quadrature Capital position in Q2 2026.
  • Voyager Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1495 holding.
  • Quadrature Capital first reported a position in Voyager Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Quadrature Capital's Voyager Therapeutics position peaked at $120K in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.